|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Marin JJ, Sanchez de Medina F, Castano B,
Bujanda L, Romero MR, Martinez-Augustin O, Moral-Avila RD and Briz
O: Chemoprevention, chemotherapy, and chemoresistance in colorectal
cancer. Drug Metab Rev. 44:148–172. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Andre T, Boni C, Navarro M, Tabernero J,
Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F
and de Gramont A: Improved overall survival with oxaliplatin,
fluorouracil, and leucovorin as adjuvant treatment in stage II or
III colon cancer in the MOSAIC trial. J Clin Oncol. 27:3109–3116.
2009. View Article : Google Scholar
|
|
4
|
Okamura H, Tsutsi H, Komatsu T, et al:
Cloning of a new cytokine that induces IFN-gamma production by T
cells. Nature. 378:88–91. 1995. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sugie T, Murata-Hirai K, Iwasaki M, Morita
CT, Li W, Okamura H, Minato N, Toi M and Tanaka Y: Zoledronic
acid-induced expansion of gammadelta T cells from early-stage
breast cancer patients: effect of IL-18 on helper NK cells. Cancer
Immunol Immunother. 62:677–687. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dao T, Ohashi K, Kayano T, Kurimoto M and
Okamura H: Interferon-gamma inducing factor, a novel cytokine,
enhances Fas ligand-mediated cytotoxicity of murine T helper 1
cells. Cell Immunol. 173:230–235. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tsutsui H, Nakanishi K, Matsui K,
Higashino K, Okamura H, Miyazawa Y and Kaneda K: IFN-gamma-inducing
factor up-regulates Fas ligand-mediated cytotoxic activity of
murine natural killer cell clones. J Immunol. 157:3967–3973.
1996.PubMed/NCBI
|
|
8
|
Kohyama M, Saijyo K, Hayasida M, Yasugi T,
Kurimoto M and Ohno T: Direct activation of human
CD8+cytotoxic T lymphocytes by interleukin-18. Jpn J
Cancer Res. 89:1041–1046. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yoshimura K, Hazama S, Iizuka N, Yoshino
S, Yamamoto K, Muraguchi M, Ohmoto Y, Noma T and Oka M: Successful
immunogene therapy using colon cancer cells (colon 26) transfected
with plasmid vector containing mature interleukin-18 cDNA and the
Igkappa leader sequence. Cancer Gene Ther. 8:9–16. 2001. View Article : Google Scholar
|
|
10
|
Choi IK, Lee JS, Zhang SN, Park J, Sonn
CH, Lee KM and Yun CO: Oncolytic adenovirus co-expressing IL-12 and
IL-18 improves tumor-specific immunity via differentiation of T
cells expressing IL-12Rbeta2 or IL-18Ralpha. Gene Ther. 18:898–909.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wirth T, Parker N and Yla-Herttuala S:
History of gene therapy. Gene. 525:162–169. 2013. View Article : Google Scholar
|
|
12
|
Beltinger C, Fulda S, Kammertoens T, Meyer
E, Uckert W and Debatin KM: Herpes simplex virus thymidine
kinase/ganciclovir-induced apoptosis involves ligand-independent
death receptor aggregation and activation of caspases. Proc Natl
Acad Sci USA. 96:8699–8704. 1999. View Article : Google Scholar
|
|
13
|
Ladjemi MZ, Jacot W, Chardes T, Pelegrin A
and Navarro-Teulon I: Anti-HER2 vaccines: new prospects for breast
cancer therapy. Cancer Immunol Immunother. 59:1295–1312. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen SH, Kosai K, Xu B, Pham-Nguyen K,
Contant C, Finegold MJ and Woo SL: Combination suicide and cytokine
gene therapy for hepatic metastases of colon carcinoma: sustained
antitumor immunity prolongs animal survival. Cancer Res.
56:3758–3762. 1996.PubMed/NCBI
|
|
15
|
Zhang JH, Wan MX, Yuan JY and Pan BR:
Construction and identification of recombinant vectors carrying
herpes simplex virus thymidine kinase and cytokine genes expressed
in gastric carcinoma cell line SGC7901. World J Gastroenterol.
10:26–30. 2004.
|
|
16
|
Xu Y, Hou J, Liu Z, Yu H, Sun W, Xiong J,
Liao Z, Zhou F, Xie C and Zhou Y: Gene therapy with tumor-specific
promoter mediated suicide gene plus IL-12 gene enhanced tumor
inhibition and prolonged host survival in a murine model of Lewis
lung carcinoma. J Transl Med. 9:392011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hall SJ, Canfield SE, Yan Y, Hassen W,
Selleck WA and Chen SH: A novel bystander effect involving tumor
cell-derived Fas and FasL interactions following Ad.HSV-tk and
Ad.mIL-12 gene therapies in experimental prostate cancer. Gene
Ther. 9:511–517. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tsutsui H, Matsui K, Kawada N, Hyodo Y,
Hayashi N, Okamura H, Higashino K and Nakanishi K: IL-18 accounts
for both TNF-alpha- and Fas ligand-mediated hepatotoxic pathways in
endotoxin-induced liver injury in mice. J Immunol. 159:3961–3967.
1997.PubMed/NCBI
|
|
19
|
Wirth T, Kuhnel F and Kubicka S:
Telomerase-dependent gene therapy. Curr Mol Med. 5:243–251. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hara T, Noma T, Yamashiro Y, Naito K and
Nakazawa A: Quantitative analysis of telomerase activity and
telomerase reverse transcriptase expression in renal cell
carcinoma. Urol Res. 29:1–6. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hazama S, Noma T, Wang F, Iizuka N, Ogura
Y, Yoshimura K, Inoguchi E, Hakozaki M, Hirose K, Suzuki T and Oka
M: Tumour cells engineered to secrete interleukin-15 augment
anti-tumour immune responses in vivo. Br J Cancer. 80:1420–1426.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Oka M, Iizuka N, Yamamoto K, et al: The
influence of interleukin- 6 on the growth of human esophageal
cancer cell lines. J Interferon Cytokine Res. 16:1001–1006.
1996.PubMed/NCBI
|
|
23
|
Toshimitsu H, Iizuka N, Yamamoto K,
Kawauchi S, Oga A, Furuya T, Oka M and Sasaki K: Molecular features
linked to the growth-inhibitory effects of gemcitabine on human
pancreatic cancer cells. Oncol Rep. 16:1285–1291. 2006.PubMed/NCBI
|
|
24
|
Corbett TH, Griswold DP Jr, Roberts BJ,
Peckham JC and Schabel FM Jr: Tumor induction relationships in
development of transplantable cancers of the colon in mice for
chemotherapy assays, with a note on carcinogen structure. Cancer
Res. 35:2434–2439. 1975.PubMed/NCBI
|
|
25
|
Araki A, Hazama S, Yoshimura K, Yoshino S,
Iizuka N and Oka M: Tumor secreting high levels of IL-15 induces
specific immunity to low immunogenic colon adenocarcinoma via
CD8+T cells. Int J Mol Med. 14:571–576. 2004.PubMed/NCBI
|
|
26
|
Correale P, Cusi MG, Del Vecchio MT, et
al: Dendritic cell-mediated cross-presentation of antigens derived
from colon carcinoma cells exposed to a highly cytotoxic multidrug
regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and
leucovorin, elicits a powerful human antigen-specific CTL response
with antitumor activity in vitro. J Immunol. 175:820–828. 2005.
|
|
27
|
Ji Q, Castelli L and Goverman JM: MHC
class I-restricted myelin epitopes are cross-presented by Tip-DCs
that promote determinant spreading to CD8(+) T cells. Nat Immunol.
14:254–261. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wahl LM and Kleinman HK: Tumor-associated
macrophages as targets for cancer therapy. J Natl Cancer Inst.
90:1583–1584. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Coughlin CM, Salhany KE, Wysocka M, Aruga
E, Kurzawa H, Chang AE, Hunter CA, Fox JC, Trinchieri G and Lee WM:
Interleukin-12 and interleukin-18 synergistically induce murine
tumor regression which involves inhibition of angiogenesis. J Clin
Invest. 101:1441–1452. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ochs K and Kaina B: Apoptosis induced by
DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and
Fas/caspase-8 independent. Cancer Res. 60:5815–5824.
2000.PubMed/NCBI
|
